Polypharmacy in Geriatric Oncology

tibbi onkoloji ozel 13-4 kapak

Neziha ULUSOYLARa, Fatma Sena DOST GÜNAYa, Pınar SOYSALb

aDokuz Eylül Üniversitesi Tıp Fakültesi, Geriatri BD, Yaşlanan Beyin ve Demans Ünitesi, İzmir, TÜRKİYE
bBezmiâlem Vakıf Üniversitesi Tıp Fakültesi, Geriatri BD, İstanbul, TÜRKİYE

ABSTRACT
The growing incidence of comorbidities related to the prolongation of life span brings out the risk of polypharmacy. Problems caused by polypharmacy could be more severe in elderly patients due to changes in the pharmacokinetics and pharmaceutical effects of drugs. Especially in elderly patients with malignant disease, new drugs are added to the list because of cancer symptoms and chemotherapy related complications. Polypharmacy leads to increased overall mortality related to increased frailty and increased number of falls and decreased quality of life and mobility in the elderly. Drug-drug and disease-drug interactions might become inevitable when herbal medications, vitamin tablets and drugs without prescription are involved. Hospital administrations and the cost of treatments also rise along with the increased number of drugs that are used. Elderly patients should be thoroughly evaluated with a multidisciplinary approach using detailed geriatric assessment tools, and drugs that are either useless or potentially harmful should be disposed along the way. Geriatritians, oncologists and especially family practitioners should give heed to the proper management and possible interactions of drugs that are used.
Keywords: Polypharmacy; adverse drug reaction reporting systems ; drug interactions

Referanslar

  1. Soysal P, Işık A.T., Geriatri Pratiğinde Geriatrik Sendromlar. Izmir: US Akademi. 2018. p.7 - 50.
  2. Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013:1-9. [Crossref]  [PubMed]
  3. Roughead EE, Vitry AI, Caughey GE, Gilbert AL. Multimorbidity, care complexity and prescribing for the elderly. Aging Health. 2011;7(5):695-705. [Crossref]
  4. Steinman MA, Lee SJ, John Boscardin W, Miao Y, Fung KZ, Moore KL, et al, Patterns of multimorbidity in elderly veterans. J Am Geriatr Soc. 2012;60:1872-80. [Crossref]  [PubMed]  [PMC]
  5. [May 2, 2013]; Meriam Webster Medical Dictionary. At [Link]
  6. Masnoon N, Shakib S, Kalisch-Ellett L., and Caughey GE, What is polypharmacy? A systematic review of definitions, BMC Geriatr. 2017;17:230. [Crossref]  [PubMed]  [PMC]
  7. Viktil KK, Blix HS, Moger TA, Reikvam AR; Polypharmacy as commonly is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187-95. [Crossref]  [PubMed]  [PMC]
  8. Maher RL, Hanlon J, Hajjar ER: Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65. [Crossref]  [PubMed]  [PMC]
  9. Jørgensen TL, Herrstedt J, Friis S, Hallas J. Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol. 2012;3(1):33-40. [Crossref]
  10. US Department of Health and Human Services. "Profile of older Americans. 2015
  11. Hanigan MH, Dela Cruz BL, Thompson DM, Farmer KC, Medina PJ. Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation. J Oncol Pharm Pract. 2008;14(3):123-30. [Crossref]  [PubMed]  [PMC]
  12. Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM.Polypharmacy And Potentıally Inapproprıate Medıcatıon Use In Gerıatrıc Oncology, J Geriatr Oncol. 2016;7(5):346-53. [Crossref]  [PubMed]  [PMC]
  13. Hanlon JT, Pieper CF, Hajjar ER, Sloane RJ, Lindblad CI, Ruby CM, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay, J Gerontol A Biol Sci Med Sci. 2006; 61(5):511-5. [Crossref]  [PubMed]
  14. Nightingale G, Hajjar E, Swartz K, AndrelSendecki J, Chapman A., Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33(13):1453-9 [Crossref]  [PubMed]
  15. Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15(5):507-22 [Crossref]  [PubMed]  [PMC]
  16. Tam-McDevitt J. Polypharmacy, aging, and cancer. Oncology (Williston Park). 2008;22(9):1052-5.
  17. Maggiore RJ, Dale W, Gross CP, Feng T, Tew WP, Mohile SG, et al. Polypharmacy and Potentially Inappropriate Medication Use among Older Adults with Cancer Undergoing Chemotherapy: Impact on Chemotherapy-Related Toxicity and Hospitalization During Treatment, J Am Geriatr Soc. 2014;62(8): 1505-12. [Crossref]  [PubMed]  [PMC]
  18. Herrsted J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007;101:43-50. [Crossref]  [PubMed]
  19. Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim of febrile neutropenia, grade IV neutropenia, and bone pain. A meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;24:2283-95. [Crossref]  [PubMed]
  20. Bennett CL, Silver SM,Djulbegovic B, Samaras AT, Blau CA,Gleason KJ,et al. and Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoietin administration for the treatment of cancer-related anemia. JAMA. 2008;299:2814-24. [Crossref]  [PubMed]
  21. Maggiore RJ, Gross CP, Hurria A., Polypharmacy in Older Adults with Cancer, Oncologist. 2010;15(5):507-22. [Crossref]  [PubMed]  [PMC]
  22. Mohile SG, Fan L, Reeve E, Jean-Pierre P, Mustian K, Peppone L, et al. Association of cancer with geriatric syndromes in older Medicare beneficiaries., J Clin Oncol. 2011;10; 29(11):1458-64. [Crossref]  [PubMed]  [PMC]
  23. Johnell K,Klarin I, The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish prescribed drug register Drug Saf. 2007;30 pp. 911-8. [Crossref]  [PubMed]
  24. Halvorsen KH, Granas AG,Engeland A, Ruths S, Prescribing quality for older people in Norwegian nursing homes and home nursing services using multidose dispensed drugs, Pharmacoepidemiol Drug Saf, 2012;21, pp. 929-36. [Crossref]  [PubMed]
  25. Kaufmann CP, Tremp R, Hersberger KE, LAmpert ML: Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014;70(1):1-11 [Crossref]  [PubMed]
  26. Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010;32:575-580. [Crossref]  [PubMed]
  27. Yap KY, Chui WK, Chan A; Onco-Informatics Group. Development of a chemotherapy regimen interaction database for the mobile Internet: detecting interactions with psychotropics through OncoRxMI. Inform Health Soc Care. 2011;36:132-146. [Crossref]  [PubMed]
  28. Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother. 2010;44:957-63. [Crossref]  [PubMed]
  29. Unutmaz GD, Soysal P, Tuven B, Isik AT, Costs of medication in older patients: before and after comprehensive geriatric assessment., Clin Interv Aging. 2018;9;13:607-13. [Crossref]  [PubMed]  [PMC]
  30. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227-46. [Crossref]  [PubMed]
  31. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P., STOPP/START criteria for potentially inappropriate prescribing in older people: version 2., Age Ageing. 2015;44(2):213-8. [Crossref]  [PubMed]  [PMC]
  32. In: Editor Book NCCN Clinical Practice Guidelines in Oncology - Older Adult Oncology. NCCN.org; City: 2015. Network NCC NCCN Clinical Practice Guidelines in Oncology - Older Adult Oncology
  33. Justin P. Turner, Sepehr Shakib, J. Simon Bell, Is my older cancer patient on too many medications?, Geriatr Oncol (2016), [Crossref]
  34. Lindsay J, Dooley M, Martin J, Fay M, A, Kearney A, Barras M, Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches, Support Care Cancer. 2014 22:1113-9. [Crossref]  [PubMed]
  35. Karuturi MS, Holmes HM, Lei X, Johnso M, Barcenas CH , Cantor SB, et al, Potentially Inappropriate Medication Use in Older Patients With Breast and Colorectal Cancer, Cancer. 2018;15;124(14):3000-7. [Crossref]  [PubMed]  [PMC]
  36. Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug- drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013;47:324-32. [Crossref]  [PubMed]
  37. Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol. 2007;25:1858-69. [Crossref]  [PubMed]
  38. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-34. [Crossref]  [PubMed]
  39. Lamy PP. Modifying drug dosage in elderly patients. In: Covington TR, Walker 11, editors. Current geriatric therapy. Philadelphia: W.B. Saunders Company. 1984: 35-72.
  40. Lindeman RD. Overview: renal physiology and pathophysiology of aging. Am J Kidney Dis. 1990;16:275. [Crossref]  [PubMed]
  41. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M., International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14. [Crossref]  [PubMed]
  42. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2005; 11:449. [Crossref]  [PubMed]
  43. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91:710-7. [Crossref]  [PubMed]
  44. Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North. 2000;14:45. [Crossref]  [PubMed]
  45. R.B Stewart, J.W Cooper, Polypharmacy in the aged. Practical solutions Drugs Aging. 19944; pp.449-61. [Crossref]  [PubMed]
  46. M.E Corcoran, Polypharmacy in the older patient with cancer Cancer Control. 19974; pp. 419-28
  47. Blower P, de Wit R, Goodin S, Aapro M. Drugdrug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;2:117-42. [Crossref]  [PubMed]
  48. Tay XY, Si P, Chew L. Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy. J Geriatr Oncol. 2015;6(4):280-7. [Crossref]  [PubMed]
  49. J.H. Beijnen, J.H. SchellensDrug interactions in oncology Lancet Oncol. 20048; pp. 489-496 [Crossref]  [PubMed]
  50. K.A. Marr, W. Leisenring, F. Crippa, J.T. Slattery, L. Corey, M. Boeckh, et al.Cyclophosphamide metabolism is affected by azole antifungals Blood, 103 (4) (2004), pp. 1557- 1559 [Crossref]  [PubMed]
  51. I.H. Stockley Methotrexate-NSAID interaction. Drug Intell Clin Pharm, 1987;21:(6), p.: 546 [Crossref]  [PubMed]
  52. R.E. Brummett, Effects of antibiotic-diuretic interactions in the guinea pig model of ototoxicity Rev Infect Dis, 3 (Suppl.) (1981), pp. S216-S223 [Crossref]
  53. A. Marcath, TD Coe, EK Hoylman, BG Redman, DL. Hertz, Prevalence of drugdrug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials, BMC Cancer. 201818:1155.
  54. Bruno JJ, Ellis JJ. Herbal use among us elderly: 2002 National Nealth Interview Survey. Ann Pharmacother. 2005;39:643-8. [Crossref]  [PubMed]
  55. Elmer GW, Lafferty WE, Tyree PT et al. Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. Ann Pharmacother. 2007;41:1617-24. [Crossref]  [PubMed]  [PMC]
  56. lone Epidemiology Center. Patterns of Medication Use in the United States A Report of the Slone Survey. Boston, MA: Slone Epidemiology Center at Boston University; 2006. [Link]
  57. Nahin RL, Fitzpatrick AL, Williamson JD, Burke GL, Dekosky ST, Furberg C, Use of herbal medicine and other dietary supplements in community-dwelling older people: baseline data from the ginkgo evaluation of memory study. J Am Geriatr Soc. 2006;54: 1725-35. [Crossref]  [PubMed]
  58. Qato DM, Alexander GC, Conti RM et al. Use of prescription and over-the- counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867-78. [Crossref]  [PubMed]  [PMC]